ФАРМАКОЭКОНОМИЧЕСКОЕ ОБОСНОВАНИЕ ЭФФЕКТИВНОСТИ ПРИМЕНЕНИЯ ВАКЦИНЫ УЛЬТРИКС® ДЛЯ ПРОФИЛАКТИКИ ЗАБОЛЕВАЕМОСТИ ГРИППОМ И ОСТРЫМИ РЕСПИРАТОРНЫМИ ВИРУСНЫМИ ИНФЕКЦИЯМИ

The article presents the results of evaluation of the preventive efficacy and pharmacoeconomic analysis of Ultrix vaccine use for prevention acute respiratory infections (ARI) and influenza in a large industrial enterprise. The case-control study included 192 people (main group) expirienced ARI or influenza in autumn-winter season 2014 -2015 and 808 people (control group) without cases of ARI or influenza during study period and randomly selected according to pre-established procedures. Ultrix was prescribed to 108 people of control group, and to 10 people of main group. The risk of acute respiratory disease or influenza within 22 days after a single prophylactic use Ultrix was 2,808 times less compared with no use of drug. Pharmacoeconomic analysis showed that prophylactic use of Ultrix in company with personnel number of 2,000 people would save 1 786,1 thousand rubles for 6 months. The results indicate a high preventive efficacy of Ultrix and economic feasibility of its use as a prophylactic agent of nonspecific acute respiratory infections and influenza.